Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective ways to treat cancer. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with one or more potential strategic partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. We are primarily focused on commercializing PIXUVRI® (pixantrone) in the European Union, or the E.U., for multiply relapsed or refractory aggressive non-Hodgkin lymphoma, or NHL, and conducting a Phase 3 clinical trial of pacritinib for the treatment of myelofibrosis. Our most clinically advanced compound is PIXUVRI. PIXUVRI is a novel aza-anthracenedione derivative that is structurally related to anthracyclines and anthracenediones, but does not appear to be associated with the same level of cardiotoxic effects. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-1.98 |
| Quarterly EPS Est: | -0.17 |
| PEG Ratio: | .00 |
|
Mean Recommendation: View Summary / View All |
1 |
Data is provided by Zacks Investment Research

